Treatment of chronic diabetic lower leg ulcers with activated protein C: A randomised placebo-controlled, double-blind pilot clinical trial

International Wound Journal

Volumn 12, Issue 4, 2015, Pages 422-427

  Whitmont, Kaley ^a   Mckelvey, Kelly J ^a   Fulcher, Gregory ^a   Reid, Ian ^a   March, Lyn ^b   Xue, Meilang ^a   Cooper, Alan ^a   Jackson, Christopher J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Activated protein C; Diabetes; Ulcer; Wound healing

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; PLACEBO; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; PROTEIN C;

ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC FOOT; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEG ULCER; LONG TERM CARE; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN BIOPSY; STRESS; AGED; CASE REPORT; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY; WOUND HEALING;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DIABETIC FOOT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEG ULCER; MALE; MIDDLE AGED; PILOT PROJECTS; PROTEIN C; WOUND HEALING;

EID: 84942549408     PISSN: 17424801     EISSN: 1742481X     Source Type: Journal    
DOI: 10.1111/iwj.12125     Document Type: Article

References (27)

1. Mulder G, Tallis AJ, Marshall VT, Mozingo D, Phillips L, Pierce GF, Chandler LA, Sosnowski BK. Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen 2009;17:772-9.
2. Taub PJ, Silver L, Weinberg H. Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis. Plast Reconstr Surg 2000;105:1034-42.
3. Hanft JR, Pollak RA, Barbul A, van Gils C, Kwon PS, Gray SM, Lynch CJ, Semba CP, Breen TJ. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 2008;17:30-2, 34-7.
4. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res 2009;153:347-58.
5. Yoshida S, Matsumoto K, Tomioka D, Bessho K, Itami S, Yoshikawa K, Nakamura T. Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model. Growth Factors 2004;22:111-9.
6. Richard JL, Parer-Richard C, Daures JP, Clouet S, Vannereau D, Bringer J, Rodier M, Jacob C, Comte-Bardonnet M. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 1995;18:64-9.
7. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, Kam G, Leung L, Chan CW, Chu CM, Lam EK. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003;26:1856-61.
8. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg 2006;56:394-8; discussion 9-400.
9. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995;21:71-8; discussion 9-81.
10. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:822-7.
11. Ortho-McNeil Pharmaceuticals Inc. Regranex Gel 0.01% (becaplermin) prescribing information including boxed warning and medication guide. URL http://www.regranex.com/PI_Full_Versionpdf. Oct. 2011 [Accessed on 19 September 2012].
12. Whitmont K, Reid I, Tritton S, March L, Xue M, Lee M, Fulcher G, Sambrook P, Slobedman E, Cooper A, Jackson C. Treatment of chronic leg ulcers with topical activated protein C. Arch Dermatol 2008;144:1479-83.
13. Xue M, Campbell D, Sambrook PN, Fukudome K, Jackson CJ. Endothelial protein C receptor and protease-activated receptor-1 mediate induction of a wound-healing phenotype in human keratinocytes by activated protein C. J Invest Dermatol 2005;125:1279-85.
14. Xue M, Thompson P, Kelso I, Jackson C. Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. Exp Cell Res 2004;299:119-27.
15. Julovi SM, Xue M, Dervish S, Sambrook PN, March L, Jackson CJ. Protease activated receptor-2 mediates activated protein C-induced cutaneous wound healing via inhibition of p38. Am J Pathol 2011;179:2233-42.
16. Jackson CJ, Xue M, Thompson P, Davey RA, Whitmont K, Smith S, Buisson-Legendre N, Sztynda T, Furphy LJ, Cooper A, Sambrook P, March L. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen 2005;13:284-94.
17. Wijewardena A, Vandervord E, Lajevardi SS, Vandervord J, Jackson CJ. Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. Int J Low Extrem Wounds 2011;10:146-51.
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
19. Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992;15:1598-604.
20. Schmidt-Supprian M, Murphy C, While B, Lawler M, Kapurniotu A, Voelter W, Smith O, Bernhagen J. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur Cytokine Netw 2000;11:407-13.
21. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-203.
22. Minhas N, Xue M, Fukudome K, Jackson CJ. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J 2010;24:873-81.
23. Xue M, Campbell D, Jackson CJ. Protein C is an autocrine growth factor for human skin keratinocytes. J Biol Chem 2007;282:13610-6.
24. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
25. Gabazza EC, Takeya H, Deguchi H, Sumida Y, Taguchi O, Murata K, Nakatani K, Yano Y, Mohri M, Sata M, Shima T, Nishioka J, Suzuki K. Protein C activation in NIDDM patients. Diabetologia 1996;39:1455-61.
26. Jaksa PJ, Mahoney JL. Quality of life in patients with diabetic foot ulcers: validation of the Cardiff Wound Impact Schedule in a Canadian population. Int Wound J 2010;7:502-7.
27. Price P, Harding K. Cardiff Wound Impact Schedule: the development of a condition-specific questionnaire to assess health-related quality of life in patients with chronic wounds of the lower limb. Int Wound J 2004;1:10-7.